ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.